Perivascular Stem Cells Suppress Inflammasome Activation during Inflammatory Responses in Macrophages

Jeeyoung Kim¹, Woo Jin Kim¹, Kwon-Soo Ha², Eun-Taek Han¹, Won Sun Park⁴, Se-Ran Yang⁵, Seok-Ho Hong¹

¹Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, Korea
²Scripps Korea Antibody Institute and Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, Korea
³Department of Medical Environmental Biology and Tropical Medicine, School of Medicine, Kangwon National University, Chuncheon, Korea
⁴Department of Physiology, School of Medicine, Kangwon National University, Chuncheon, Korea
⁵Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kangwon National University, Chuncheon, Korea

Background and Objectives: Perivascular stem cells (PVCs) have been identified as precursors of mesenchymal stem cells (MSCs) that offer promising prospects for application in the development of cellular therapies. Although PVCs have been demonstrated to have greater therapeutic potential compared to bone marrow and adipose tissue-derived MSCs in various diseases, the regulatory role of PVCs on inflammasome activation during macrophage-mediated inflammatory responses has not been investigated.

Methods and Results: In this study, we found that the PVC secretome effectively alleviates secretion of both caspase-1 and interleukin-1β in lipopolysaccharide-primed and activated human and murine macrophages by blocking inflammasome activation and attenuating the production of mitochondrial reactive oxygen species (ROS). We further showed that the PVC secretome significantly reduces inflammatory responses and endoplasmic reticulum stress in peritoneal macrophages in a mouse model of monosodium urate-induced peritonitis. A cytokine antibody array analysis revealed that the PVC secretome contains high levels of serpin E1 and angiogenin, which may be responsible for the inhibitory effects on mitochondrial ROS generation as well as on inflammasome activation.

Conclusions: Our results suggest that PVCs may be therapeutically useful for the treatment of macrophage- and inflammation-mediated diseases by paracrine action via the secretion of various biological factors.

Keywords: Perivascular stem cells, Inflammation, Inflammasome, Macrophage

Introduction

The inflammatory response is a process that perceives “danger” signals via binding to a cognate specific receptor, and thereby is able to fight back in self-defense; this process is highly sensitive to tissue injury and also protects the host from excessive inflammation. Inflammasomes are important regulators of innate immunity, with an important function during inflammation in vivo (1). Their assembly is triggered when a member of the NOD-like receptor (NLR) proteins (NLRP1 and NLRP3) and non-NLR receptors, such as absent in melanoma-2 (AIM2), are
activated (2). Upon activation, these innate immune sensor proteins oligomerize, leading to the recruitment of an adaptor protein such as apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), which then binds with pro-caspase-1 to form an inflammasome. Inflammasome assembly promotes pro-caspase-1 cleavage to generate the active form, which leads to promoting of caspase-1 (Casp1)-dependent inflammatory cell death, termed pyroptosis, and the secretion of pro-inflammatory cytokines, such as interleukin (IL)-1β or IL-18. Accordingly, the aberrant activation of the inflammasome is a risk factor for the emergence of autoimmune, autoimmune, chronic inflammatory, and metabolic diseases (3-6).

Mesenchymal stem cells (MSCs) exhibit multipotency with immunomodulatory and anti-inflammatory activity, which make them attractive for treating many diseases (7, 8). MSCs migrate to sites of tissue injury and produce various immunosuppressive factors such as tumor necrosis factor-α (TNF-α), indoleamine 2,3-dioxygenase, and prostaglandin E-2 (PGE-2) (9). Evidently, MSCs ameliorate inflammatory diseases by suppressing inflammasome activation in various tissues. Adipose tissue (AD)-derived MSCs were found to ameliorate chronic colitis by the reduction of total number of macrophages and M1 macrophages, mediated through the inhibitory action of PGE-2 on inflammasome complex formation in macrophages (10). In a rat spinal cord injury model, transplantation of Wharton’s jelly-derived MSCs was found to suppress the NLRP1 inflammasome and improve motor function recovery (11). Moreover, human umbilical cord (HUC)-derived MSCs have been shown to effectively reduce inflammatory responses through blocking NLRP3 inflammasome activation for therapies in type 2 diabetes (12). In recent years, accumulating evidence indicates that perivascular stem cells (PVCs), as a precursor of MSCs, offer promising prospects for their application in the development of cellular therapies due to their greater proliferative activity and regeneration potential compared to AD- and bone marrow (BM)-derived MSCs (13, 14). PVCs can be isolated from various fetal and adult tissues and are being extensively investigated in a number of preclinical studies for various diseases (15, 16). However, the therapeutic effects of PVCs on macrophage-mediated inflammatory diseases have been poorly investigated. Thus, given the beneficial anti-inflammatory properties of MSCs and greater therapeutic potential of PVCs, it is imperative to investigate the possibility that PVCs could suppress inflammasome activity during macrophage-mediated inflammatory responses.

In this study, we confirmed in vitro that PVCs effectively attenuate the secretion of pro-inflammatory cytokines in human and murine macrophages by suppressing inflammasome activation in a paracrine fashion. We also demonstrated that the PVC secretome significantly reduces inflammatory activity and endoplasmic reticulum (ER) stress in peritoneal macrophages in a monosodium urate (MSU)-induced peritonitis mouse model. Secretome analysis of PVCs revealed serpin E1 and angiogenin as potential factors for inhibiting mitochondrial reactive oxygen species (ROS) generation and inflammasome activation. Our findings provide a rationale for the possible application of PVCs in the treatment of macrophage- and inflammation-mediated diseases by paracrine action via the secretion of various biological factors.

Materials and Methods

PVC isolation and cultures

Unless otherwise indicated, all materials for PVC culture were purchased from Gibco (Thermo Fisher Scientific Inc., MA, USA). The study was approved by the institutional review board of Kangwon National University Hospital (2012-11-003-008). All participants provided written informed consent. As previously described (15), PVCs were isolated from HUC obtained following full-term birth after caesarian section. PVC purification was confirmed by FACS to represent >87%, CD146+ populations and be free of CD45+, CD34+, CD31− cells. PVCs were maintained with α-MEM medium containing 10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin at 37°C in a 5% CO₂ atmosphere. All PVCs were studied at low passages (P3~P5).

Preparation of PVC-conditioned medium

To prepare conditioned medium (CM) from PVC cultures, when PVC cultures reached about ~70~80% confluence, the cells were washed once with phosphate-buffered saline (PBS), followed by incubation with α-MEM supplemented free medium. After 24 h, CM was harvested and concentrated using Amicon Ultra-15 Centrifugal Filter Units (Merck Millipore, Billerica, Massachusetts, USA) for 60 min at 6,000 g, 4°C. After filtering through a 0.22-μm filter (Merck Millipore), the final concentrated CM measured with approximately 10- to 12-fold for experimental studies. The concentration of the CM was determined using the BCA assay (Thermo Fisher Scientific Inc). The protein concentration of the prepared medium was then adjusted to 60 mg/ml for experiments. An equal amount of concentrated CM was diluted with RPMI 1640 at a volume ratio of 1:3 (concentrated CM: THP-1 cells...
media). It is usually useful to evaluate CM by making several serial dilutions.

**Cell culture and inflammasome activation**

A human peripheral blood-derived monocytic cell line, THP-1, was obtained from the Korea Cell Line Bank (KCLB No. 40202; Seoul, Republic of Korea) and these cells were differentiated into macrophage-like cells by incubating with phorbol 12-myristate 13-acetate (PMA, 100 nM, InvivoGen, CA, USA) for 72 h. Mouse peritoneal macrophages were obtained from C57BL/6 mice as described below for the MSU-induced peritonitis model. The PMA-differentiated THP-1 cells and mouse peritoneal macrophages were plated on 12-well plates (Falcon, USA) and primed with 1 μg/ml of lipopolysaccharide (LPS; Sigma-Aldrich Co., MO, USA) in RPMI 1640 containing 10% FBS and antibiotics for 3 h. The cells were then stimulated with NLRP3, NLRC4, AIM2 activator ATP (2 mM; InvivoGen), flagellin (500 μg/ml; InvivoGen), or dsDNA (2 μg/ml; pGL3 plasmid vector) for 1 h. To determine the inhibitory effects of PVC-CM (dosages of 20 μg/ml to 5 μg/ml), rhSerine E1 (2 unit/Rx, Novous, CO, USA), or rhAngiogenine (2 unit/Rx, R&D system, MN, USA) on inflammasome activation, the extracts were co-treated with the above activators. Cellular supernatant (Sup), lysate (Lys), and pellets (Pellet) cross-linked with suberic acid bis (Sigma-Aldrich Co.) were collected for further analysis.

**Western blot analysis**

Samples were separated on an SDS-PAGE gel (12% or 15%), transferred into PVDF membrane (Millipore, Billerica, MA, USA) and blocked. Then, the membrane was probed with primary antibodies against anti-human/mouse IL-1β antibody (AF-201-NA/AF-401-NA, R&D systems), anti-caspase-1 p20 antibody (ab207802, Abcam, Cambridge, UK), anti-ASC antibody (sc-22514, Santa Cruz Biotechnology, CA, USA), anti-caspase-1 antibody (sc-622, Santa Cruz Biotechnology), anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology) overnight at 4°C, the membranes were further probed with HRP-conjugated 2nd antibody (Sigma-Aldrich, St Louis, MO, USA) and visualized by western blot detection kit (WEST-SAVESTAR, Seoul, Republic of Korea) and ChemiDoc™ MP Imaging System (Bio-Rad Laboratories, Inc.).

**Cytotoxicity test**

For cytotoxicity assay, THP-1 cells (2×10^6 cells/well) allowed to be attached in 96-well plates to 90% confluence. The cells were treated with the indicated substances for 3 hrs and cytotoxicity was assessed by MTS assay (Abcam) according to the manufacturer’s protocol.

**Enzyme-linked immunosorbent assay (ELISA)**

To quantitate secreted IL-1β and Caspase-1/ICE, cell culture supernatants from PMA-differentiated THP-1 cells and mouse peritoneal macrophages were measured using the human IL-1β and human Caspase-1/ICE Quantikine ELISA Kit (R&D Systems). The ELISA plates were read-out using a microplate reader (Molecular Devices, CA, USA).

**Caspase-1 activity assay**

For caspase-1 activity assay, human recombinant caspase-1 (1 unit/rx, #1081, BioVison Inc., CA, USA) was incubated with YVAD-pNA, a substrate of caspase-1, in the presence of PVC-CM, Serpin E1, Angiogenin or Z-VAD-FMK (10 μM, tlrl-vad, InvivoGen). The activity of caspase-1 was measured by Caspase-1/ICE Colorimetric Assay Kit (#K111, BioVison Inc) according to the manufacturer’s protocol.

**Quantitative real-time PCR**

PMA-differentiated THP-1 cells and mouse peritoneal macrophages (1×10^6 cells/well) in 6 well-culture plates have primed the absence or presence of 100 ng/ml LPS for 3 hrs with a dosage of PVC-CM. Total RNA was extracted using Trizol (Invitrogen) and reverse-transcribed into cDNA using the QuantiTect® reverse transcription kit according to the manufacturer’s protocol (Qiagen, Hilden, Germany). Transcripts were quantitated using Power SYBR® Green PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) and the QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems). Primer sequences are listed in Table 1. All of the quantitation was normalized with β-actin.

**Mitochondria ROS analysis**

PMA-differentiated THP-1 cells were plated on Poly-L-Lysine (Sigma)-coated confocal dish (SPL Life Science Co., Gyeonggi-do, Republic of Korea) and 12 well plates for 3 days and then LPS primed cells were treated with Rotenone (10 μM, Sigma) or candidate inhibitors for 6 h. For confocal microscopy, the cells were loaded with Mitosox (2.5 μM, Invitrogen) and Mitotracker Green (100 nM, Invitrogen) probes for 30 min at 37°C. After washing three times with PBS, followed by a replacement cellular medium. Images were analyzed by Korea basic science institute chequeon center (LSM 780 confocal microscope, Carl Zeiss, NY, USA).
Table 1. Primer sequences used for quantitative RT-PCR

| Genes  | Sequence 5’ to 3’ | Product size (bp) |
|--------|-------------------|------------------|
| IL-1 α | F CCG ACC TCA TTT TCT TCT GC | 104 |
|        | R GTG CAC CCG ACT TTG TTC TT |         |
| IL-1 β | F CCC AAG CAA TAC CCA AAG AA | 133 |
|        | R GCT TGT GCT CTT GTG AG |         |
| NLRP3  | F CAG GCC AGA CCT CTC GGA AA | 123 |
|        | R CCC AGC AAA CCC ACT AC |         |
| Casp1  | F AGA TGG CAC ATT TCC AGG AC | 221 |
|        | R GAT CCT CCA GCA GCA ACT AC |         |
| ATF6   | F GGA CGA GGT GGT TCT AGA G | 62 |
|        | R GAC AGC TCT TCG CTT TGG AC |         |
| PERK   | F CCT TGG TTT CAT CTA GCC TCA | 110 |
|        | R ATC CAG GGA GGG GAT GAT |         |
| EIF2 α | F CCA AGC AGT TTG GCT ACT GA | 96 |
|        | R TGT TAA ATT CCC AGA AGA AGA TGA |         |
| IRE1   | F TGA AAC ACC CCT TCT TCT GC | 78 |
|        | R CCT CTT TTA TTC GGT CAC TT |         |
| Actb   | F AGC CAT GTA CTT AGC CAT CC | 228 |
|        | R CTC TCA GCT GTG GTG GTG AA |         |

Proteome profiling analysis

To search for candidate factors, cytokine assay was performed using the human XL Cytokine Antibody Array (R&D system). Briefly, PVC-CM and activated cell supernatants were incubated with the array's membrane, following the manufacturer's protocol. A schematic representation of the cytokine/chemokine spot positions in duplicate on the membrane with respective internal controls. Dots were detected using ChemiDoc MP Imaging System (Bio-Rad Laboratories, Inc.), and dots intensity were analyzed by Image J software.

Animals study and peritoneal macrophage isolation

C57BL/6 mice were obtained from Dooyeol Biotech (Seoul, Republic of Korea). All animals used for the experiments were aged 6–8 weeks. All animal studies were conducted in compliance with the guidelines of the committee for the care and use of experiments on animals and approved by the Institutional Animal Care and Use Committee at the Kangwon National University. To generate the MSU-induced inflammatory disease model, mice were administered an intraperitoneal (IP) injection of 3% thioglycollate (3 ml) for priming. After 4 days, the mice were IP injected MSU (5 mg/mouse) with/without PVC-CM in 0.2 ml PBS for 6 h. For the white blood cell (WBC) differential count, mice were anesthetized by isoflurane (Aesica Queen Borough Limited, Kent, UK), and whole blood was collected from the orbital sinus. Mice were euthanized by cervical dislocation, and the peritoneal exudate cells were harvested from peritoneal cavity lavage fluid with 8 ml Opti-MEM medium. Whole blood and peritoneal exudate cells were analyzed by WBC differential count (XN-3000, Sysmex, Japan) and Wright-Giemsa staining.

Statistical analysis

Statistical analyses were performed with Student’s t-test and two-way analysis of variance for multiple groups using GraphPad Prism (GraphPad Software, San Diego, CA, USA). Data were collected from at least three independent experiments and represent the mean±SD. p<0.05 was considered to be significant.

Results

PVC-CM inhibits the inflammasome activation during macrophage-mediated inflammatory response in a paracrine fashion

The MSC secretome has been widely applied in various preclinical studies as an acceptable alternative, because MSCs transplanted to site of injury mainly act via indirect paracrine effects. Thus, we first asked if the CM collected from PVC cultures could regulate inflammasome activation during macrophage-mediated inflammatory responses in vitro. Inflammasome activation is a two-step process: first, it requires a priming step, which leads to intracellular synthesis of NLRP3, pro-casp1, and pro-IL-1β. Next, a second activation step results in the assembly of the inflammasome complex and induced Casp-1 and IL-1β activation that can be stimulated by various triggers (Fig. 1A). We first treated LPS-primed human macrophages (PMA-differentiated THP-1 cells) with PVC-CM in the absence and presence of inflammasome activators. As shown in Fig. 1B, PVC-CM alone did not mediate the secretion of the active form of IL-1β (p17) in THP-1 cells, whereas ATP, a well-known NLRP3 inflammasome activator, significantly induced IL-1β secretion. To elucidate whether PVC-CM acts as an inhibitor for the NLRP3, NLRC4, and AIM2 inflammasomes, we treated inflammasomes triggered in LPS-primed human macrophages with PVC-CM and measured the active forms of Casp1 and IL-1β. PVC-CM significantly inhibited Casp1 and IL-1β secretion mediated by several inflammasome activators, and also attenuated the formation of the ASC pyroptosome (Fig. 1C). The attenuation of Casp1 and IL-1β secretion by PVC-CM was further confirmed by ELISA (Fig. 1D and 1E). Similarly, PVC-CM attenuated inflammasome activation and IL-1β
secretion in mouse peritoneal macrophages (Fig. 2A and 2B). Furthermore, PVC-CM treatment significantly reduced Casp1 activity without affecting cell survival (Fig. 2C and 2D). These results suggest that PVCs have anti-inflammatory activity through the suppression of inflammasome activation, which is a conserved mechanism in human and murine macrophages.

**PVC-CM relieves inflammation and ER stress in macrophages of MSU-induced peritonitis**

To determine whether PVCs are able to control inflammation through inflammasome activation in vivo, we evaluated the expression of inflammasome components and inflammatory cytokines in macrophages of experimental peritonitis model (Fig. 3A). Initially, we evaluated the total white blood cell count in peritoneal fluid from control- and inflamed mice, which reflects inflammation and the associated potential for tissue damage. As shown in Fig. 3B and 3C, MSU enhanced the total number of peritoneal exudate cells (PECs) and the infiltration of macrophages into the peritoneum, and this was significantly inhibited by PVC-CM treatment. In addition, the elevated expression levels of inflammatory cytokines (IL-1α and IL-1β), inflammasome components (NLRP3 and Casp1), and ER stress-related genes were significantly down-regulated in peritoneal macrophages of PVC-treated peritonitis mice compared to MSU-treated controls (Fig. 3D and 3E). These results suggest that PVCs can suppress inflammatory responses and ER stress by controlling the migration and activation of macrophages, and may be therapeutically useful for the treatment of inflammatory diseases.

**PVC-CM treatment reduces IL-1β secretion in human macrophages through regulation of serpin E1 and angiogenin secretion**

To identify which soluble factors play roles in the regulation of inflammatory responses and inflammasome activation, a human cytokine array was performed with the supernatant of human macrophage cultures treated with...
either PVC-CM alone or with ATP in the presence and absence of PVC-CM. The results identified serpin E1 and angiogenin as predominant candidates (Fig. 4A), and their association with the suppression of inflammation and inflammasome activation was investigated in human macrophages either at the LPS priming step or at the ATP li-
Fig. 4. Secretome analysis. Proteome profiler arrays were evaluated as described in Methods. (A) The heat map represents the subsequent image analysis and quantification of pixel intensity for each spot. (B, C) LPS-primed THP-1 cells treated with inflammasome triggers in the absence or presence of rhSerpin E1 or rhAngiogenin for 1 h. IL-1β levels in the supernatants were measured by ELISA. (D) Caspase-1 activity was determined by colorimetric assay. Error bars indicate SD (*p < 0.05, **p < 0.01, ***p < 0.001).

censing step. Treatment with serpin E1 or angiogenin significantly reduced the secretion of IL-1β in human macrophages (Fig. 4B and 4C). However, angiogenin had no effect on the activity of Casp1, whereas high-dose serpin E1 treatment significantly inhibited Casp1 activity (Fig. 4D). These results suggest that PVCs control inflammation in macrophages through the regulation of serpin E1 and angiogenin secretion.
PVC-CM suppresses NLRP3 inflammasome activation through mitochondrial ROS production in macrophages

Activation of the NLRP3 inflammasome is positively regulated by a common pathway of ROS (17). Thus, we asked whether PVC-CM, serpin E1, and angiogenin have a suppressive effect on NLRP3 inflammasome activation via regulation of mitochondrial ROS. We first examined the effects of DPI, an inhibitor of mitochondria-derived and NOX-dependent ROS production, on IL-1β release in human macrophages stimulated with ATP. As expected, IL-1β expression was blocked in DPI-treated macrophages stimulated with ATP (Fig. 5A). Similarly, PVC-CM also inhibited IL-1β expression in macrophages with rotenone-induced NLRP3 activation (Fig. 5B). We further confirmed, using luminescence and confocal analysis, that PVC-CM and angiogenin significantly attenuated the production of mitochondrial ROS resulting from rotenone treatment in human macrophages, whereas serpin E1 had no effect on ROS production (Fig. 5C and 5D). Collective-

Fig. 5. The Mechanism underlying the inhibitory effect of PVC-CM on NLRP3 inflammasome via mitochondrial ROS generation. (A) LPS-primed THP-1 cells treated with ATP (2 mM) and the indicated DPI (100 to 10 μM) for 1 h. Sup and Lys were analyzed by immunoblot using the indicated anti-sera. (B) LPS-primed THP-1 cells were treated with rotenone (20 μM) and the indicated dosages of PVC-CM for 6 h, after which mitochondrial ROS generation was analyzed by immunoblot. (C) Mitochondrial ROS (MitoSOX) were quantified using a fluorometric microplate reader. (D) Relative fluorescence intensities of Mito Tracker (mitochondria) and MitoSOX (mitochondrial ROS) were analyzed using confocal microscopy. Hoechst was used for nuclear staining. Error bars indicate SD (*p<0.05, **p<0.01, ***p<0.001).
ly, these results suggest that PVC-mediated ROS inhibition may suppress the activation of the NLRP3 inflammasome.

**Discussion**

Multipotent PVCs have a definite advantage in being used for the treatment of various diseases and regulation of the tissue microenvironment. Recent studies have indicated that PVC deficiency is associated with irreversible blood retina barrier breakdown and initiates sustained inflammation, thereby indicating the pathological role of PVCs in various disorders such as diabetes, Alzheimer’s or ischemic tissues injuries (18). In addition, a recent report showed that PVCs control inflammatory and fibrotic responses to tissue injury via regulation of MyD88 and IRAK4 expression (19). Although the greater therapeutic potential of PVCs compared to BM- and AD-MSCs has been well demonstrated in various diseases, the regulatory role of PVCs on inflammasome activation during macrophage-mediated inflammatory responses has not been investigated. In the present study, we demonstrated that PVCs derived from HUC had potent inhibitory activity on inflammation and inflammasome activation in macrophages using in vitro and in vivo models. Our results are consistent with previous studies suggesting that MSCs attenuate the NLRP3 inflammasome via mitochondrial ROS damage (20). Similarly, our findings showed that the PVC-CM reduced Casp-1-dependent IL-1β secretion via inactivation of the NLRP3 inflammasome as well as the NLRC4 and AIM2 inflammasomes, suggesting that it acts on the upstream of ASC oligomerization to suppress a direct indicator of inflammasome activation. Furthermore, PVC-CM had inhibitory effects on mitochondrial ROS production, which is a critical step or upstream event for NLRP3 activation. Taken together, the PVC secretome might be a versatile tool to study inflammasome biology and may prove therapeutically useful for the treatment of inflammatory diseases.

In this study, secretome analysis revealed angiogenin as a potential molecule regulating inflammatory responses and ROS production. Angiogenin has been well characterized as a angiogenic factor in tumor growth and is induced by other angiogenic factors including vascular endothelial growth factor and epidermal growth factor (21). Angiogenin was also detected in the secretomes of human MSCs and has been found to be important for enhancing the regenerative potential of MSCs in various diseases, as well as in repairing vascular injury (22-25). Moreover, several lines of evidence suggest that angiogenin is involved in the innate immune system and is associated with inflammatory activation. For example, Angiogenin exerts anti-inflammatory activity in TNF-α and LPS-inflamed human corneal fibroblasts by suppressing NF-κB nuclear translocation through the inhibition of TANK-binding kinase 1 expression (26). In addition, it has been reported that the protein level of angiogenin in serum is increased during inflammatory responses, which may support the anti-inflammatory role of angiogenin (27, 28). Although angiogenin has shown a variety of biological activities including anti-inflammatory and antiviral activities via different molecular pathways, the effects of angiogenin on inflammasome activation have not been investigated. Here, we have shown that angiogenin attenuates the secretion of IL-1β through the activation of the NLRP3 inflammasome as well as the production of mitochondrial ROS, suggesting a new perspective for the regulation of inflammasome activation in inflammatory diseases.

In our study, we employed a macrophage cell line, as well as macrophages harvested from mice with MSU-induced peritonitis, to evaluate the effects of PVC and angiogenin on NLRP3, NLRC4, or AIM2 inflammasome activation. Previous findings demonstrated that AD-MSCs ameliorate colitis by suppression of inflammasome complex formation, which is due to the M1-to-M2 macrophage transition and reduction in the total number of macrophages (10). In fact, the therapeutic effects of MSCs in various inflammatory disease models was attributed to M1 to M2 macrophage polarization and infiltration of macrophages to injury sites (29-31). Thus, further study is needed to confirm the anti-inflammatory capacity of PVCs and angiogenin in controlling the macrophage population. In the present study, we found that PVC secretome effectively reduced the secretion of pro-inflammatory cytokines in human and murine macrophages by suppressing inflammasome activation. We further demonstrated that the PVC secretome significantly reduced inflammatory activity and endoplasmic reticulum (ER) stress in peritoneal macrophages. These results support that PVC secretome could act as a versatile tool to study inflammasome biology and for the treatment of inflammatory diseases.

**Acknowledgments**

This study was supported by grants from the Ministry of Science, ICT and Future Planning (2015R1A4A1038666), the National Research Foundation of Korea (NRF) funded by the Korean government (MIST) (2019R1A2C2005453) and the Global PhD Fellowship Program through the (NRF funded by the Ministry of Education (2018H1A2A1063441).
Potential Conflict of Interest
The authors have no conflicting financial interest.

References

1. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265
2. Chen G, Shaw MH, Kim YG, Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009;4:365-398
3. Yang CA, Chiang BL. Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun 2015;61:1-8
4. Broderick L, De Nardo D, Franklin BS, Hoffman HM, Latz E. The inflammasomes and autoinflammatory syndromes. Annu Rev Pathol 2015;10:395-424
5. Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappell F, Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, ChungKF, Barnes PJ, Papi A, Adcock I, Balbi B. Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 2014;69:516-524
6. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140
7. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD. MSCs: Biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev 2011;10:93-103
8. Yi TG, Cho YK, Lee HJ, Kim J, Jeon MS, Ham DS, Kim WC, Song SU. A novel immunomodulatory mechanism dependent on acetylcholine secreted by human bone marrow-derived mesenchymal stem cells. Int J Stem Cells 2019;12:315-330
9. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013;91:19-26
10. Park HJ, Kim J, Saima FT, Rhee KJ, Lazzari L, Huard J, Péault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-313
11. Mohamadi Y, Noori Moghahi SMH, Mousavi M, Borhani-Haghighi M, Abolhassani F, Kashani IR, Hassanzadeh G. Intrathecal transplantation of Wharton’s jelly mesenchymal stem cells suppresses the NLRP1 inflammasome in the rat model of spinal cord injury. J Chem Neuroanat 2019;97:1-8
12. Sun X, Hao H, Han Q, Song X, Liu J, Dong L, Han W, Mu Y. Human umbilical cord-derived mesenchymal stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochem Biophys Res Commun 2018;498:988-995
13. Mohamadi Y, Noori Moghahi SMH, Mousavi M, Borhani-Haghighi M, Abolhassani F, Kashani IR, Hassanzadeh G. Intrathecal transplantation of Wharton’s jelly mesenchymal stem cells suppresses the NLRP1 inflammasome in the rat model of spinal cord injury. J Chem Neuroanat 2019;97:1-8
14. Kim JY, Lee JY, Ha KS, Han ET, Park WS, Min CK, Hong SH. Perivascular cells and NADPH oxidase inhibition partially restore hyperglycemia-induced alterations in hematopoietic stem cell and myeloid-derived suppressor cell populations in the bone marrow. Int J Stem Cells 2018;12:63-72
15. An B, Kim E, Song H, Ha KS, Han ET, Park WS, Ahn TG, Yang SR, Na S, Hong SH. Gestational diabetes affects the growth and functions of perivascular stem cells. Mol Cells 2017;40:434-439
16. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007;25:1384-1392
17. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-225
18. Ogura S, Kurata K, Hattori Y, Takase H, Ishiguro-Oonuma T, Hwang Y, Ahn S, Park I, Ikeda W, Kusuhara S, Fukushima Y, Nara H, Sakai H, Fujiiwara T, Matsushita J, Ema M, Hirashima M, Minami T, Shibuya M, Takakura N, Kim P, Miyata T, Ogura Y, Uemura A. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight 2017;2:e90905
19. Leaf IA, Nakagawa S, Johnson BG, Cha JJ, Mittelsteadt K, Guckian KM, Gomez IG, Altemeier WA, Duffield JS. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J Clin Invest 2017;127:321-334
20. Oh JY, Ko JH, Lee HJ, Yu JM, Choi H, Kim MK, Wee WR, Prockop DJ. Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells 2014;32:1553-1563
21. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005;24:445-456
22. Mihi MC, Popa MA, Suica VI, Antohe F, Jackson EK, Simionescu M, Dubey RK. Mechanism of 17β-estradiol stimulated integration of human mesenchymal stem cells in heart tissue. J Mol Cardiol 2019;133:115-124
23. Kim HK, Lee SG, Lee SW, Oh BJ, Kim JH, Kim JA, Lee G, Jang JD, Joe YA. A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells. Stem Cells 2019;37:77-88
24. Chang PY, Zhang BY, Cui S, Qu C, Shao L, Xu TK, Ku YQ, Dong L, Wang J. MSC-derived cytokines repair radiation-induced intra-villi microvascular injury. Oncotarget 2017;8:87821-87836
25. Zhang Y, Xia X, Yan J, Yan L, Lu C, Zhu X, Wang T, Yin T, Li R, Chang HM, Qiao J. Mesenchymal stem cell-derived angiogenin promotes primordial follicle survival and angiogenesis in transplanted human ovarian tissue.
26. Lee SH, Kim KW, Min KM, Kim KW, Chang SI, Kim JC. Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells. MEDIATORS INFLAMM 2014;2014:861435

27. Oikonomou KA, Kapsoritakis AN, Kapsoritaki AI, Manolakis AC, Tsiopoulou FD, Tsiompanidis IA, Potamianos SP. Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. INFLAMM BOWEL DIS 2011;17:963-970

28. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. CLIN CANCER RES 2000;6:3545-3551

29. Yin Y, Hao H, Cheng Y, Zang L, Liu J, Gao J, Xue J, Xie Z, Zhang Q, Han W, Mu Y. Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. CELL DEATH DIS 2018;9:760

30. Ahn SY, Park WS, Kim YE, Sung DK, Sung SI, Ahn JY, Chang YS. Vascular endothelial growth factor mediates the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicles against neonatal hyperoxic lung injury. EXP MOL MED 2018;50:26

31. Lee SE, Jang JE, Kim HS, Jung MK, Ko MS, Kim MO, Park HS, Oh WI, Choi SJ, Jin HJ, Kim SY, Kim YJ, Kim SW, Kim MK, Sung CO, Park CG, Lee KU, Koh EH. Mesenchymal stem cells prevent the progression of diabetic nephropathy by improving mitochondrial function in tubular epithelial cells. EXP MOL MED 2019;51:1-14